KRAS and lung adenocarcinoma: By investigating the transcriptomic data from The Cancer Genome Atlas (TCGA) dataset, we validated a statistically significant increase of c-Myc expression in KRAS mutant lung adenocarcinoma (LUAD, n = 356) and COAD (n = 173), compared to KRAS wild-type LUAD (n = 155) and COAD (n = 229) respectively, indicating that c-Myc amplification was positively correlated with KRAS mutation in cancer (Fig. 1F).